Maximum Daily Dose of Lisinopril
The maximum daily dose of lisinopril is 40 mg once daily for all indications including hypertension, heart failure, and post-myocardial infarction. 1
FDA-Approved Maximum Dosing
The FDA label explicitly states that lisinopril should be titrated "as tolerated to a maximum of 40 mg once daily" across all approved indications. 1 This represents the regulatory ceiling for lisinopril dosing, and doses above 40 mg have not been studied in clinical trials and are not recommended. 1
Target Dosing by Indication
Heart Failure with Reduced Ejection Fraction
- Target dose: 20-35 mg once daily for optimal mortality benefit 2, 3
- The ATLAS trial demonstrated that high-dose lisinopril (32.5-35 mg daily) was superior to low-dose (2.5-5 mg daily), reducing death or hospitalization by 12% and heart failure hospitalizations by 24% 2, 4
- At minimum, achieve 50% of target dose (10 mg daily) for meaningful clinical benefit 3
- Start at 5 mg once daily (or 2.5 mg if hyponatremic with sodium <130 mEq/L), then titrate every 2 weeks as tolerated 1, 3
Hypertension
- Target dose: 20-40 mg once daily 1
- Start at 10 mg once daily (or 5 mg if on diuretics) 1
- If blood pressure remains uncontrolled at 40 mg daily, add hydrochlorothiazide 12.5-25 mg rather than exceeding the maximum lisinopril dose 1
Post-Myocardial Infarction
- Target dose: 10 mg once daily (after initial titration) 1
- Initiate at 5 mg within 24 hours of symptom onset, followed by 5 mg at 24 hours, 10 mg at 48 hours, then 10 mg daily for at least 6 weeks 1
- Start at 2.5 mg if systolic BP is 100-120 mmHg 1
Dose Adjustments for Renal Impairment
Critical consideration: Renal function directly impacts lisinopril dosing since the drug is eliminated primarily by the kidneys without hepatic metabolism. 5, 6
- CrCl >30 mL/min: No dose adjustment needed; maximum 40 mg daily 1
- CrCl 10-30 mL/min: Start at half the usual dose (5 mg for hypertension, 2.5 mg for heart failure/MI), titrate to maximum 40 mg daily as tolerated 1
- CrCl <10 mL/min or hemodialysis: Start at 2.5 mg once daily, titrate cautiously to maximum 40 mg daily 1
The elimination half-life of lisinopril (12.6 hours) is prolonged in renal impairment, necessitating these adjustments. 5
Monitoring Requirements During Titration
Essential monitoring parameters to safely reach maximum doses:
- Check blood pressure, serum creatinine, and potassium within 5-7 days after initiation or dose increases 2
- An increase in creatinine up to 50% above baseline is acceptable and does not require dose reduction 3
- Monitor potassium levels closely, especially with concomitant potassium-sparing diuretics or supplements 3, 1
- Continue monitoring at 3 months, then every 6 months during maintenance therapy 2
Special Populations
Elderly Patients
- No specific dose reduction required based on age alone 7
- Dosages of 2.5-40 mg/day are effective, with 68-89% of elderly patients responding to treatment 7
- More gradual titration may be prudent due to increased risk of hypotension 7
Pediatric Patients (≥6 years)
- Maximum dose: 0.61 mg/kg once daily (not to exceed 40 mg total) 1
- Start at 0.07 mg/kg once daily (up to 5 mg) 1
- Not recommended in children <6 years or with GFR <30 mL/min/1.73m² 1
Common Pitfalls to Avoid
Underdosing is widespread in clinical practice, with less than 25% of heart failure patients ever titrated to target doses. 8 This represents a missed opportunity for mortality reduction, as the dose-response relationship is clear: higher doses provide greater benefits than lower doses. 2, 4
Do not exceed 40 mg daily under any circumstances. If blood pressure or heart failure symptoms remain uncontrolled at maximum dose, add complementary agents (diuretics, beta-blockers) rather than exceeding the FDA-approved maximum. 1
Asymptomatic hypotension does not require dose reduction. Only symptomatic hypotension warrants intervention, and in such cases, consider reducing diuretic dose before lowering lisinopril. 3
Never combine lisinopril with other ACE inhibitors or ARBs in acute settings (e.g., post-MI), as this increases adverse effects without added benefit. 3